Healthcare -
Biotechnology - NASDAQ - US
$ 9.33
2.08 %
$ 465 M
Market Cap
-2.55
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Mineralys Therapeutics, Inc.
| Net Income | -178 M |
| Depreciation & Amortization | 43 K |
| Capital Expenditures | -96 K |
| Stock-Based Compensation | 11.3 M |
| Change in Working Capital | 9.52 M |
| Others | -307 K |
| Free Cash Flow | -166 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (177.8) | (71.9) | (29.8) | (19.4) | (3.4) |
| Depreciation & Amortization | 43 K | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 11.3 | 5.1 | 0.5 | 80 K | 1 K |
| Other Operating Activities | (9.4) | (6.9) | (0.6) | 0.7 | 0.5 |
| Change in Working Capital | 9.5 | (7.5) | 0.8 | 4.1 | 0.5 |
| Cash From Operations | (166.3) | (81.2) | (29.2) | (14.6) | (2.5) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | 96 K | 0 | 0 | 0 | 0 |
| Other Items | 115.1 | (160.5) | (21.8) | 0 | 0 |
| Cash From Investing Activities | 115.0 | (160.5) | (21.8) | 0 | 0 |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | (1.6) | 0 | 20 K |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 83 K | 0.5 | 129.6 | 23.8 | 3.8 |
| Cash From Financing Activities | 116.1 | 203.2 | 128.0 | 23.8 | 3.8 |
| CHANGE IN CASH | |||||
| Net Change In Cash | 64.8 | (38.4) | 77.0 | 9.3 | 1.4 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (166.4) | (81.2) | (29.2) | (14.6) | (2.5) |